Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;23(12):1861-1876.
doi: 10.1007/s11864-022-01036-1. Epub 2022 Nov 16.

Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma

Meghan M Lynch  1 , Borislav A Alexiev  2 , Brett A Schroeder  3 , Seth M Pollack  4
Affiliations
Review

Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma

Meghan M Lynch et al. Curr Treat Options Oncol. 2022 Dec.

Abstract

While no PD-1 inhibitor has been FDA approved for use in sarcoma or proven efficacious in a randomized trial, the use of single agent PD-1 inhibitors is standard-of-care and recommended by the NCCN guidelines in certain specific subtypes and situations. Even while the role of immunotherapy is still being defined in sarcoma, there is rising interest in combinations of PD-1 inhibitors with standard-of-care treatments, especially chemotherapy. Recently, several early phase trials have suggested potential benefits for chemotherapy in combination with PD-1 inhibitors. Although some physicians are already combining PD-1 inhibitors and chemotherapy for sarcoma off-label in the community, we believe more data is necessary. We support further evaluation of these combinations in well-designed clinical trials.

Keywords: Chemotherapy; Combination therapy; Immune checkpoint inhibitor; Immunotherapy; Sarcoma.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Katz D, Palmerini E, Pollack SM. More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments. Am Soc Clin Oncol Educ Book. 2018;38:925–38. https://doi.org/10.1200/EDBK_205423 . - DOI
    1. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. https://doi.org/10.1016/S0140-6736(13)60106-3 . - DOI
    1. Ayodele O, Razak ARA. Immunotherapy in soft-tissue sarcoma. Curr Oncol. 2020;27(Suppl 1):17–23. https://doi.org/10.3747/co.27.5407 . - DOI
    1. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovee J, et al. Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127(16):2934–42. https://doi.org/10.1002/cncr.33618 . - DOI
    1. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200–29. https://doi.org/10.3322/caac.21605 . - DOI

LinkOut - more resources